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2ABSTRACT
Antibiotics That Inhibit 30S or 50S Ribosomal Subunit Formation in Bacteria:
hygromycin B, quinupristin-dalfopristin and XRP 2868
by
Susan Mabe McGaha
Several antibiotics that prevent translation by binding to ribosomal subunits have
been shown to also inhibit ribosomal subunit assembly (Champney and Tober
2003).  The aminoglycoside hygromycin B was examined in Escherichia coli cells
for inhibitory effects on translation and ribosomal subunit assembly.  The
streptogramin antibiotics quinupristin-dalfopristin and XRP 2868 (NXL 103) were
examined for similar effects on these 2 cellular functions in antibiotic-resistant
strains of Haemophilus influenzae, Staphylococcus aureus, and Streptococcus
pneumoniae.
Pulse chase experiments were performed which verified slower rates of
ribosomal subunit formation in drug treated cells. Hygromycin B exhibited a
concentration dependent inhibitory effect on viable cell number, growth rate,
protein synthesis and 30S and 50S subunit formation. 16S rRNA specific probes
hybridized to rRNA fragments in cells treated with hygromycin B.  RNase II and
RNase III deficient strains of E. coli exhibited the most accumulation of 16S rRNA
fragments upon treatment with hygromycin B.  Examination of total RNA from
3treated cells showed an increase in RNA corresponding to precursor to the 16S
rRNA while 16S rRNA decreased.  There was also an increase in small fragment
RNA.  Hygromycin B was a more effective inhibitor of translation than ribosomal
subunit formation in E. coli.
Two streptogramin antibiotics were compared for inhibitory effects in
antibiotic-resistant Haemophilus influenzae, Staphylococcus aureus, and
Streptococcus pneumoniae. IC50 values for XRP 2868 were several fold lower
than those of quinupristin-dalfopristin for inhibition of cell viability, protein
synthesis, and ribosomal subunit formation.  Both antibiotics revealed a
concentration dependent inhibitory effect on cellular functions including 50S
ribosomal subunit formation in the three organisms examined.
XRP 2868 inhibited both 50S ribosomal subunit assembly and translation.
XRP 2868 was effective against MRSA and was a better inhibitor in each of the
antibiotic resistant strains examined compared with quinupristin-dalfopristin.
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 CHAPTER 1
INTRODUCTION
Ribosomes are the biological structures responsible for the manufacture of
proteins within cells.  The bacterial ribosome is formed from two subunits having
sedimentation coefficients of 30S (small subunit) and 50S (large subunit).  These
subunits are ribonucleoprotein complexes, consisting of ribosomal RNA (rRNA)
and ribosomal proteins.  Figure 1 illustrates the prokaryotic ribosome.  For many
years the ribosome function in translation has been a target for antimicrobial
drugs.  Overuse and negligent use of antibiotics coupled with the fast
evolutionary rate of bacteria and their ability to adapt to new onslaughts have
resulted in an increase in antimicrobial resistance creating a major problem for
human welfare.
Currently, only a small number of antibiotics are available to treat multi-
drug resistant strains of bacteria, but resistance to even the newest antimicrobial
agents is appearing (Hancock 2005).  Increasing antibiotic resistance in microbial
populations has necessitated the search for alternate cellular targets for new and
existing antimicrobial agents.   One novel target is ribosomal subunit assembly.
There are many antibiotics available that inhibit translation in bacterial cells by
binding to the 30S or 50S ribosomal subunit.  In several cases it has been
observed that these drugs also posses a second inhibitory activity that is
stopping ribosomal subunit assembly.  The formation of a functional ribosome is
12
a vital cellular process and is therefore also an important cellular drug target
(Champney 2003).
Figure 1  The Prokaryotic Ribosome.  The prokaryotic ribosome is assembled in
cells from 30S subunits made from 16S rRNA and proteins and 50S subunits
consisting of 23S and 5S rRNA and proteins.
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Several studies have been carried out with inhibitors of 50S and 30S
subunit assembly.  Recent work with the macrolides, ketolides, lincosamides and
streptogramin B compounds has reveled that these antibiotics affect 50S subunit
assembly specifically (Champney and Tober 1998; Champney and Tober 2000).
Studies by Mehta and Champney (2002; 2003) also found that aminoglycosides
have a second inhibitory target that is preventing 30S subunit formation.  Figure
2 (A-B) illustrates a proposed model for inhibition of ribosomal subunit formation
by inhibitors of 30S and 50S ribosomal subunits.  Comparison studies with
several antibiotics from each class have provided useful insights into structure-
activity relationships that could lead to novel drug development targeting
ribosomal subunit assembly.  To broaden our understanding of subunit assembly
inhibitors, it is important to examine new or poorly studied antibiotics for their
possible effects on inhibition of subunit formation.   Identifying and comparing
these antimicrobial agents will aid in the search to find more suitable targets for
future antibiotics.
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Figure 2  Models for 30S and 50S ribosomal subunit assembly inhibition by
antibiotics.  Inhibition of 30S (A) and 50S (B) ribosomal subunit assembly. (i)
Subunit formation in control cells (ii) Subunit formation in antibiotic treated cells.
Antibiotics may bind to one of two inhibitory sites, the fully formed ribosomal
subunit inhibiting translation (top panel), or an intermediate particle halting
assembly of the ribosomal subunit (bottom panel).
16S rRNA Fragments
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There are many antibiotics that target translation by binding to ribosomal
subunits that have not been examined for possible inhibitory effects on ribosomal
subunit assembly.  Among those antimicrobial agents are the aminoglycoside
hygromycin B, a 30S subunit inhibitor, and the streptogramin compounds
quinupristin-dalfopristin (Synercid) and XRP2868 (NXL 103) affecting the 50S
subunit.
Hygromycin B has a structure that is different from most aminoglycosides.
Classic aminoglycosides are characterized by two differential amino-sugar rings
that are connected to a 2-deoxystreptamine ring (Figure 3A).  The position at
which the two variable rings are attached determines the class of aminoglycoside
to which the compound belongs.  Hygromycin B is unusual in its structure having
instead two ether linkages connecting two of its three sugar residues resulting in
a fourth, 5-membered ring (Figure 3B).  This extended structure has been shown
recently to bind to the 30S ribosomal subunit near the A, P and E sites and spans
a 13 Å distance on the small subunit (Figure 4) (Brodersen and others 2000).
Hygromycin B has been in use since 1957 as the first additive in livestock
feed to be approved by the Food and Drug Administration. It has been used
extensively since then as a growth aid and parasite control agent in the
production of swine and poultry.  The compound removes parasites by disrupting
the egg laying process and then killing the adults.  Eliminating ova production
ensures that pens and lots will not be contaminated with eggs, a problem
associated with other one-dose parasite removal options (Kelly and Olsen 1960;
16
Biehl 1986; Lamb and others 1999).  Hygromycin B has also been used in the
laboratory to select for recombinant cells containing a hygromycin B resistance
marker (Gritz  and Davies  1983).  Importantly it may also be an effective inhibitor
of ribosomal subunit formation.
Figure 3  Chemical structures of aminoglycoside antibiotics.  (A) The classical 2-
deoxystreptamine aminoglycosides.  (B) Hygromycin B has two ether linkages
connecting two of its three sugar residues resulting in a fourth, 5-membered ring.
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Figure 4  Crystal structure of hygromycin B bound to the small subunit.
Hygromycin B is shown bound to Thermus thermophilius 30S subunit, yellow
stick with color corresponding red (oxygen) and blue (nitrogen) balls.  Ring
structures are labeled 1-4.  Green nucleotides represent the proposed decoding
center, orange nucleotides represent mutation sites causing resistance to
hygromycin B (Cell 2000; 103:1145).
Recent studies with the aminoglycosides neomycin and paromomycin
have revealed that these drugs are capable of inhibiting 30S ribosomal subunit
formation by stalling assembly at an intermediate phase of 30S formation (Mehta
and Champney 2002; Mehta and Champney 2003).  Previous Northern
hybridization analysis with inhibitors of 50S ribosomal subunit assembly have
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shown that these antibiotics cause a decrease in the amount of mature 23S
rRNA and an accumulation of partially degraded 23S particles in antibiotic
treated cells (Champney and Burdine 1996; Champney and Burdine 1998a;
Champney and Miller 2002; Silvers and Champney 2005).  This accumulation of
rRNA fragments is the result of antibiotic binding to an intermediate particle in
ribosomal subunit assembly.  These particles are normally degraded by RNases
as illustrated in Figure 2B.  In strains deficient in RNases important for particle
turnover this process is retarded and a build up of ribosomal RNA fragments from
the stalled particle occurs.  The resulting fragments are large enough to be
examined by Northern hybirdization analysis.  Previous work has shown that
RNase II and III and PNPase are heavily involved in the turnover of 23S rRNA in
the precursor which forms in the presence of the 50S inhibitor azithromycin
(Silvers and Champney 2005).  The accumulation of 16S rRNA fragments during
treatment with 30S ribosomal subunit inhibitors has never been examined.  One
goal of this study was to determine if the 30S ribosomal subunit inhibitor
hygromycin B had any effect on accumulation of 16S rRNA fragments in E. coli
cells with loss of function mutations in RNase I, RNase III, RNase II, and PNPase
mutant strains.  The structure and mechanism of binding of hygromycin B sets
the compound apart from other aminoglycosides; therefore, it is of interest to
examine the effect these differences have on inhibition of subunit assembly and
its effects on turnover of 16S rRNA oligonucleotide accumulation in hygromycin B
treated cells.
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Other antibiotics with the potential to be specific inhibitors of ribosomal
subunit formation are the streptogramin compounds quinupristin-dalfopristin and
XRP 2868.  The chemical structures of these antibiotics are shown in Figure 5.
Streptogramin compounds have been isolated from naturally occurring sources
and have been used clinically in parts of Europe as antimicrobial agents for more
than 20 years (Leclercq and Courvalin 1998).  Streptogramin antibiotics are a
combination of two chemically distinct compounds that are administered clinically
in a 30:70 weight-to-weight ratio of group B to group A.   Each streptogramin
antibiotic is composed of a group B (or type I) and a group A (or type II)
streptogramin.  Each group has a unique binding site.  Each compound alone
has a bacteriostatic effect, but when combined the two groups act synergistically
to produce bactericidal activity (Allignet and others 1996; Malbruny and others
2002).  Group B streptogramins have been shown to bind to a site on the 50S
ribosome and block the peptide exit tunnel.  Group A streptogramins bind within
the peptidyl transferase center and interfere with positioning of substrate in the A
and P sites.  The binding of group A streptogramins also increases the binding
affinity of group B streptogramins giving a synergistic inhibitory effect. The crystal
structure of quinupristin-dalfopristin binding to the 50S subunit of Deinococcus
radiodurans has been resolved and is pictured in Figure 6 (Harms and others
2004).
Historically streptogramin compounds have been limited in their use
because of limited solubility; however, two new streptogramin compounds
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(quinupristin-dalfopristin and XRP2868) have been introduced that have
increased solubility and may be administered intravenously and orally
respectively.  Quinupristin-dalfopristin is a combination of quinupristin (derived
from pristinamycin IA) a group B streptogramin, and dalfopristin (derived from
pristinamycin IIA) a group A streptogramin that have been approved for clinical
use in the United States. Quinupristin-dalfopristin has been indicated for
treatment of vancomycin-resistant Enterococcus faecium and treatment of
complicated skin infections cause by Staphyloccus aureus or Streptococcus
pyogenes (Lamb and others 1999).  Quinupristin-dalfopristin has been shown to
be effective in treatment of antibiotic resistant infections where few other
treatment options exist ( Low 1995; Drew and others 2000).  A recent study using
a S. aureus biofilm model has shown quinupristin-dalfopristin to be more effective
than many other antibiotics against bacteria in biofilms (Pfeil and Wiedemann
2000).  XRP 2868 has also been shown to have good inhibitory activity against a
wide range of Gram-positive pathogens and some Gram-negative respiratory
tract pathogens.   XRP 2868 is one of only three antibiotics from new classes of
antimicrobial agents that have been released in the past 40 years (Lamb and
others 1999).
XRP 2868 is a mixture of 2 streptogramin compounds, RPR 132552A and
RPR 202868, that are chemically modified forms of quinupristin and dalfopristin
respectively (Figure 5).  The structural changes of XRP 2868 from quinupristin-
dalfopristin lead to better water solubility and efficacy of an oral administration
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route.  Pankuch and others (2003) compared XRP 2868 with quinupristin-
dalfopristin in Gram-positive pneumococci and Haemophilus.  Minimum inhibitory
concentrations for XRP 2868 were 2 fold lower than quinupristin-dalfopristin for
the inhibition of pneumococcial growth and 4-8 fold lower for inhibition of
Haemophilus strains (Pankuch and others 2003).   XRP 2868 is not yet available
clinically but shows superiority over quinupristin-dalfopristin in its inhibitory
activities against important resistant strains of pathogenic bacteria including
methicillin-resistant Staphylococcus aureus (MRSA), erythromycin-resistant
Streptococcus pneumoniae and b-lactamase-positive Haemophilus influenzae
(Pankuch and others 2003; Eliopoulous and others 2005; Goldstein and others
2005; Mabe and Champney 2005).  XRP 2868 has also been shown to be 4 fold
more effective than quinupristin-dalfopristin for inhibition of Enterococcus faecium
and exhibited greater efficacy in inhibition of Enterococcus faecalis (Eliopoulous
and others 2005).  In a murine lung and thigh infection model the antibiotic has
shown great effectiveness in clearing infection by multi-resistant strains of S.
pneumoniae and S. aureus (Andes and Craig 2006).
 Quinupristin-dalfopristin is already proving to be an important antibiotic in
the last line of defense against multi-drug resistant microbes.  XRP 2868,
pending clinical trials and approval from the Food and Drug Administration, will
likely also be an important resource in the clinical arsenal against the increasing
threat of multi-drug-resistant strains of pathogenic bacteria. It is possible that
inhibition of subunit formation could play a role in the success of both
22
quinupristin-dalfopristin and XRP 2868 in inhibiting the growth of these
organisms.  More potent subunit assembly inhibition is also a possible
mechanism for the increased activity of XRP 2868 against microorganisms in
comparison to quinupristin-dalfopristin.  Understanding the underlying
mechanisms behind the inhibitory effects of these new compounds is crucial for
improved drug design.  Furthermore, it is important to determine the effects of
other antimicrobials on subunit formation in order to realize the potential of this
new antibiotic target.
Figure 5  Structures of streptogramin antibiotics.  (a) quinupristin, (b) dalfopristin,
(c) RPR 202868, and (d) RPR 132552A.
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Figure 6  Crystal structure of quinupristin-dalfopristin bound to the large subunit.
Quinupristin-dalfopristin is shown bound to the 50S ribosomal subunit of
Deinococcus radiodurans in relation to the P-site and the ribosomal exit tunnel
(gold) (BioMed Central 2004; 2:4).
The goals of this study were to determine the effects of XRP 2868 and
quinupristin-dalfopristin upon cellular functions in methicillin-resistant
Staphylococcus aureus, b-lactamase-positive Haemophilus influenzae, and
erythromycin-resistant Streptococcus pneumonae.  The study also examined the
effects of hygromycin B upon cellular functions in Escherichia coli including the
effect of hygromycin B on the accumulation of 16S rRNA fragments in E. coli
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strains treated with the antibiotic.  Hygromycin B, quinupristin-dalfopristin, and
XRP 2868 have not been examined for inhibitory activity against ribosomal
subunit assembly.  I hypothesized that the translational inhibitors examined here
also posses a second target in inhibiting ribosomal subunit formation.  The
streptogramin compounds XRP 2868 and quinupristin-dalfopristin that bind to the
50S ribosomal subunit target the 50S ribosomal subunit in assembly.  The
aminoglycoside hygromycin B binds to the 30S and specifically targets this
subunit in assembly.  I also hypothesized that hygromycin B would cause an
accumulation of 16S rRNA fragments in cells treated with the antibiotic and that
this accumulation could be detected by using a Northern blotting procedure.   An
additional expectation was that of 16S rRNA fragments would be higher in strains
missing the RNases that are necessary for turnover of stalled 16S rRNA
particles.  An increase in 16S precursor and small fragment RNA and a decrease
in 16S rRNA in total RNA isolated from cells treated with hygromycin B was also
hypothesized.
Several methods were used to test these hypotheses.  Each drug’s
mechanism of action was measured via a four-part assay experiment that was
used to determine effects on cellular processes including growth rate, rate of
protein synthesis by 35S-methionine incorporation, rate of subunit formation by
3H-uridine incorporation into rRNA and cell viability.  Pulse chase kinetic analysis
with 3H-uridine labeling was used to measure rates of subunit formation in cells.
An examination of rRNA turnover in cells treated with hygromycin B was also
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performed.  Northern blotting techniques with a 16S rRNA specific biotin labeled
probe were used to show accumulation of 16S rRNA in cells treated with
hygromycin B.  RNase deficient strains were also examined to determine the
enzymes that may be involved in turnover of stalled 16S precursor particle.  Total
RNA was also examined using an Aligent Bioanalyzer 2100.  For each assay,
comparisons were made between inhibitory effects on protein synthesis relative
to subunit assembly inhibition. Information from these studies will aid in
understanding structure-activity relationships for ribosomal subunit assembly
inhibition and can also help elucidate the mechanisms cells have for recycling
rRNA that has been bound by antibiotic.  Comparing inhibitory activities of
different types of antibiotics also provides information useful in determining the
value of ribosomal subunit assembly inhibition as a possible target for future drug
development.
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CHAPTER 2
MATERIALS AND METHODS
Materials
XRP 2868 and quinupristin-dalfopristin were supplied by Aventis
Pharmaceuticals and were used as a 70:30 mixture of the A- and B-
streptogramins. Stock solutions of all antibiotics were made at 10 mg/ml in
distilled H2O.  Lysozyme, thymine, lipo-proteins, hemin, nicotinamide adenine
dinucleotide, and hygromycin B were purchased from Sigma Chemical
Corporation.  Tryptic soy broth, tryptone peptone, agar, agarose, sucrose,
Scintisafe Gel scintillation fluid, sodium dodecyl sulfate, 3-(N-Morpholino)-
propanesulfonic acid, trichloro-acetic acid, 20X saline-sodium citrate,
formaldehyde, formamide, methanol, deoxycholic acid sodium salt,
phenylmethanesulfonyl fluoride, isopropanol, Mirus Label-IT® biotin labeling kit,
Fuji medical X-ray film, and Kodak GBX developer and fixer were purchased
from Fisher.  AquaPure RNA isolation kit was purchased from Bio-Rad.  Nytran
SPC nylon transfer membranes were purchased from Scheicher & Schuell. The
North2South® chemiluminescent nucleic acid hybridization and detection kit was
purchased from Pierce. Washing & Pre-Hybridization solution and background
quencher were purchased from Molecular Research Center, Inc.  PCR primers
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were obtained from Life Technologies. The PCR Super-mix was purchased from
Gibco BRL. The GF/A glass fiber filters and blotting paper were purchased from
Whatman International.  3H-uridine (45 Ci/mmol) was purchased from New
England Nuclear.  35S-methionine (TRANS35S-LABEL 1175 Ci/mmol) was
purchased from MP Biomedical.  Low range, ready-to-use RNA ladder was
purchased from Fermentas.
Cricket Graph III software (Computer Associates) was used to construct
graphs and curves and for calculations.  Curve fitting was also performed through
Cricket Graph software.  Curve fits were chosen according to best fit.
Media
Tryptic Soy Broth:  30 g tryptic soy broth in 1 L dH2O.
Tryptic Soy Broth Plates:  1 L tryptic soy broth and 15 g agar.
5X A-salts:  52.5 g K2HPO4, 22.5 g KH2PO4, 5 g (NH4)2SO4, and 2.5 g
NaCitrate·(2H2O) to 1 L dH2O
Buffers
S-Buffer:  10 mM Tris-HCl (pH 8.0), 50 mM NH4Cl and 0.5 mM Mg Acetate.
10X MOPS Buffer:  0.2 M MOPS (pH 7.0), 20 mM sodium acetate, 10 mM EDTA
(pH 8.0).
16S rRNA Fragments
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RNA Resuspension Buffer: 150 µl formamide, 36 µl formaldehyde, 30 µl 10X
MOPS buffer.
RNA Running Buffer:  900 ml sterile dH2O, 100 ml 10X MOPS buffer.
Alkaline Transfer Buffer:  3 M NaCl, 8 mM NaOH, and 2 mM Sarkosyl.
5X Neutralizing Buffer:  79.25 g Na2HPO4, 60.25 g NaH2PO4 in 1 L dH2O
Formamide Hybridization Buffer:  50% formamide, 5X SSC, 0.1 % sarkosyl,
0.02% SDS, 200 µg/ml BSA, with 1X background quencher.
TE buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA.
Bacterial Strains
Several bacterial strains were used in this study.  Those strains are listed in
Table 1.
Table 1  Strains of bacteria used in this study
Name Genotype Phenotype Reference
Escherichia coli D10 HfrH met- rna-1
relA
RNase 1- (Gesteland
1966)
Escherichia coli
CA244
F- ∆pnp::kanR PNPase - (Reuven and
Deutscher
1993)
29
Table 1 continued
Name Genotype Phenotype Reference
Escherichia coli
SK7622
F- thyA715
rncD38::kanR
RNase III- (Babitzke and
others 1993)
Escherichia coli
SK4803
gal thi ton sup
hasdR4
endAsbcB15
rnb296
RNase II- (Donovan and
Kushner 1986)
Staphylococcus
aureus A1024
Streptococcus
pneumoniae
11591
ErmB+
Methicillin-resistant
Erythromycin-
resistant
(Champney and
Burdine 1998b)
(Champney and
others 2004)
Haemophilus
influenzae
 G79-84
b-lactamase+ Methicillin-
resistant
(Champney and
Tober 2003)
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Methods
MIC Determination
The minimal inhibitory concentration for each antibiotic was determined by
a broth dilution method as described (Champney and Burdine 1998a).  Six test
tubes were filled with 1 ml of TSB.  Each tube received 50 µl of an overnight
culture of bacterial cells and antibiotic over a range of concentrations.  The tubes
were incubated at 37°C overnight and the absorbance at 600 nm was measured.
Analysis of Cell Growth and Cell Viability
Cell cultures except S. pneumoniae were grown in a water bath at 37°C in
TSB in the presence or absence of antibiotic according to the method of
Champney and Burdine (1998a).  S. pneumoniae was grown in TSB at 37°C in 8
ml screw cap tubes.  Media were supplemented with 50 µg/ml of thymine for E.
coli strain SK7622 and with 10 µg/ml of hemin and nicotinamide adenine
dinucleotide and 0.7% lipo proteins for H. influenzae.  Growth was initiated by
adding cells from an overnight culture (~0.1-0.2 ml) to TSB growth media.
Growth rates were measured by recording the increase in cell density over time
using a Klett-Summerson colorimeter.  Cell growth was monitored over two cell
doublings at which point 10 µl was removed from the growing culture and added
to 990 µl of A-salts.  A serial dilution was performed to achieve a final dilution of
10-5 and 10 µl was plated on square TSB agar plates (Jett and others 1997).
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TSB agar plates for E. coli SK7622 and H. influenzae were supplemented with
Thymine at 50 µg/ml.  Plates were incubated for 24-48 hours at 37°C.  Colonies
were counted from control and drug treated samples to determine the effect of
the antibiotics on the viable cell number.
Analysis of the Rate of Protein Synthesis
Cell cultures were grown as described above.  After 2 cell doublings in the
presence or absence of antibiotic, 35S-methionine was added to the culture at a
concentration of 1 µCi/ml.  Three samples of 0.4 ml were removed at 5 minute
intervals after addition of the 35S-methionine.  Cells were precipitated in 20%
TCA and collected on Whatman GF/A glass fiber filters.  Filters were washed
with 10% TCA and 97% ethanol to ensure there was no free 35S-methionine on
the filters.  Filters were air dried under a heat lamp and placed in vials with 3 ml
Scintisafe fluid before being measured for radioactivity by liquid scintillation
counting.
Analysis of Ribosomal Subunit Assembly
All bacterial cells were grown as described above.  For all strains except S.
pneumoniae, a 30 ml culture of bacterial cells in TSB was started from an
overnight culture.  Cells were grown to a Klett of approximately 20 and the 30 ml
culture was split into six 5 ml cultures.  S. pneumoniae was grown in TSB at 37°C
in 8 ml screw cap tubes.  Antibiotic was added in different concentrations to
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appropriate cultures.    After 15 minutes of growth in the presence of antibiotic,
3H-uridine (1 µCi/ml) and 1 µg/ml uridine was added to the control and antibiotic
treated samples. In order to halt further isotope incorporation after 2 cell
doublings, uridine (50 µg/ml) was added in excess to each culture.  After a 15-
minute chase period, cells were spun in a Beckman centrifuge (J2-21) at 6,000
rpm for 12 minutes in a JA21 rotor.  Cell pellets were washed with sterile S-buffer
or SAS-buffer (S. aureus, and S. pneumoniae).  Washed pellets were spun again
at 6,000 rpm for 12 minutes.   The cell pellets were stored at -70°C before cell
lysis.
Different lysis procedures were used for the various strains of bacteria.
Washed cell pellets were thawed at room temperature.  E. coli and H. influenzae
cell pellets were re-suspended in 200 µl of S- buffer and 10 µl of a 5 mg/ml
solution of lysozyme was added.  S. aureus was re-suspended in 200 µl of SAS-
buffer with 20 µg lysostaphin and 15 µl of 0.1M phenylmethanesulfonyl fluoride in
isopropanol.  S. pneumoniae was re-suspended in 300 µl of SAS-buffer, 300 µg
lysozyme and 30 µl of 0.1M PMSF.  Suspended E. coli, H, influenzae, and S.
aureus cells were allowed to incubate at room temperature for 15 to 20 minutes
and were then subject to a freeze-thaw process. S. pneumoniae was incubated
for 30 minutes at 37°C.  After the incubation, 100 mg 0.1 mm sterile glass beads
and 15 µl of 10% deoxycholic acid sodium salt were added.  Cells were frozen for
5 minutes at -70°C and then thawed at room temperature.  This procedure was
repeated twice. The S. pneumoniae cells were vortexed for 1.5 minutes after
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each freeze thaw until the lysate was viscous.  DNA was digested in cell lysates
by adding 1-2 units of RNase free DNAse to each sample.  The samples were
spun at 6,000 rpm for 12 minutes to clear the lysate of cell debris.
To examine the amount of subunits in cells and the effects of antibiotics on
subunit assembly, cell lysates were centrifuged on linear sucrose gradients.
Linear sucrose gradients of 5-20 % were prepared to separate ribosome
particles.  The cleared supernatant was loaded on the top of the 5-20% linear
sucrose gradients.  Gradients were made using a Buchler gradient maker and 6
ml each of 5% and 20% sucrose in S- buffer for E. coli and H. influenzae and
SAS-buffer for S. aureus and S. pneumoniae.  The prepared gradients were
placed in a SW40 swinging bucket rotor and centrifuged in a Beckman LE80K
Ultracentrifuge at 39,000 rpm for 4.5 hours or 18,000 rpm for 18 hours.  An ISCO
Model UA-5 absorbance monitor was used to measure and record the
absorbance at 254 nm of the gradients as they were pumped through.  Fractions
of equal amounts were collected into vials and mixed with 3 ml of Scintisafe gel.
The incorporation of 3H-uridine into RNA was then measured by liquid scintillation
counting set for dual labeled samples to distinguish 3H from 35S.
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3H-uridine Pulse-Chase Kinetic Analysis of Ribosomal Subunit Formation
E.coli cells were grown in 24 ml of TSB to approximately 10 Klett units at
27°C.  50 µg/ml of hygromycin B was added to the culture.  The control sample
was grown in the absence of the antibiotic.  When the cell density reached a Klett
reading of 30, cells were pulse-labeled with 3H-uridine (1 µCi/ml) for 3 minutes
and then chased with uridine at 50 µg/ml.  Samples of 4 ml were taken from the
cultures at intervals and centrifuged at 6000 rpm for 12 minutes.  Cell pellets
were washed and stored at -70°C before cell lysis for sucrose gradient
centrifugation and liquid scintillation counting as described above.
Construction of Biotinylated 16S and 23S rRNA Specific Probes
Polymerase chain reaction (PCR) was used to amplify the 16S (241 base
pair) and 23S (146 base pair) specific probes from plasmid pKK3535 DNA.  PCR
reaction mixtures contained 45 µl PCR Supermix High Fidelity reagent mixture
(Gibco BRL), 1 µl of plasmid DNA (6.5 ng), 1 µl (10 pmol) of either the 16S or
23S forward primer, 1 µl (10 pmol) of either 16S or 23S reverse primer, and 2 µl
sterile dH2O.  Primer sequences are given in Silvers and Champney (2005).
Samples were placed in a MJ Research PTC-100 programmable thermocycler
for 35 cycles under the following conditions:  denaturation at 94°C for 30
seconds, annealing of primers to target DNA at 57°C for 30 seconds, and
extension of the primers at 72°C for 30 seconds.  The PCR products were
purified by extraction with an equal volume of phenol:CHCl3 and precipitated with
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2 volumes of pure ethanol.  The pellets were dried at 44°C for 15 minutes then
resuspended in 30 µl of sterile dH2O.  Purity of the PCR products was examined
by running 1 µl on a 2% agarose gel.  The purified DNA probes were labeled with
biotin using the Label-IT biotin labeling kit (Mirus) following the manufacturer’s
instructions.  Specificity of each probe was tested by hybridization with 23S and
16S rRNA as shown in Figure 7.  Detection of the biotin label is carried out by
using a streptavidin horseradish peroxidase conjugate as illustrated in Figure 8.
Figure 7  Assay for specificity of 16S and 23S biotin labeled probes.  (A)
Hybridization of 16S rRNA specific probe with 16S and 23S rRNA.  (B)
Hybridization of 23S rRNA specific probe with 16S and 23S rRNA.
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Figure 8  Detection of rRNA via biotin labeled 16S internal probe.  Streptavidin
horseradish peroxidase conjugate is used to illuminate biotin labeled probe
positions upon addition of peroxide substrate.
Isolation of Small RNA and Total RNA
E. coli cells were grown in 10 ml of TSB.  Cells were harvested and lysed,
and lysates were centrifuged through S-buffered sucrose gradients as described
above.  The top fractions of sucrose gradients were taken and RNA was isolated
from these fractions by phenol and chloroform extraction.  One volume of
absolute ethanol and Mg acetate to 0.01 M was added to the pool of fractions
and was allowed to stand at -20°C for 15 minutes to precipitate the RNA.
Samples were spun at 7,000 rpm for 30 minutes and the supernatant was
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discarded. The RNA pellet was resuspended in 0.5 ml TE buffer and transferred
to a 1.5 ml tube. The samples were vortexed with 5 µl 10% SDS and 0.5 ml
phenol and spun in a microcentrifuge at 10,000 rpm for 5 minutes.  The aqueous
layers were extracted and placed into new microcentrifuge tubes and the phenol
extraction repeated. The aqueous layers were placed into new tubes and 0.5 ml
of chloroform was added.  The samples were vortexed and spun at 10,000 rpm
for 5 minutes in a microcentrifuge.  The chloroform extraction was also performed
twice.  Aqueous layers were removed into new tubes and 5 µl of 5 M NH4 acetate
was added and the tubes were filled with absolute ethanol, mixed, and allowed to
stand at -70°C for 30 minutes.  Samples were spun in a cold room at 10,000 rpm
for 10 minutes.  After the addition of 0.5 ml of 70% ethanol, the samples were
spun again at 10,000 rpm for 10 minutes.  Ethanol was decanted and RNA
pellets were dried until no ethanol was detectable.  RNA was re-suspended in 25
µl of sterile water.
Total RNA was isolated from cell pellets using the AquaPure RNA isolation
kit from Bio-Rad according to the manufacturer’s directions.
Northern Analysis of 16S rRNA
RNA was isolated as described above.  The RNA (2.5-5 µg) was mixed
with 15 µl RNA resuspension buffer, heated at 55°C for 15 minutes, and then
quickly cooled on ice.  Loading dye 5 µl (80% glycerol, 1% bromo-phenol blue)
was added to the samples before loading on 1.5% agarose gels.  Top samples
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from gradients were run for 2 hours, while total RNA samples were run for 4
hours at 50 volts.  A low range RNA ladder (Fermentas) was biotin labeled using
the LableIt Kit from Mirus according to the manufacture’s directions and added to
one well for determining size of RNA fragments. RNA in the gels was examined
by soaking in 1% ethidium bromide solution and examination by UV light.
After electrophoresis, RNA from the gels was blotted onto nylon
membranes (Nytran) using a Turboblot apparatus.  Following the manufacturer’s
directions, alkaline transfer buffer was used to carry out the transfer.  After the
transfer, gels were checked for RNA.  The membranes were neutralized in 1X
neutralizing buffer and the RNA was cross-linked to the membranes using a UV
oven (Fisher-Biotech).  The membranes were placed in 50 ml plastic corex tubes
with 15 ml of 1X prehybridization solution (MRC, Inc.) and allowed to incubate at
42°C for 30 minutes in a hybridization incubator (Fisher-Biotech).  The pre-
hybridization buffer was discarded and the membranes were hybridized overnight
at 42°C in the hybridization incubator with hybridization buffer, with 1X
background quencher (MRC Inc.) and 4 pmol of denatured 23S or 16S probe.
The probe was denatured by mixing with 0.1 volume of Mirus Denaturation Buffer
D1 and incubating at room temperature for 5 minutes.  The solution was chilled
on ice and mixed with 0.1 volume Mirus Neutralization Buffer N1 and incubated
at room temperature for 5 minutes.
Following hybridization, the membranes were washed and the probe
detected using Pierce’s North2South chemiluminescent hybridization and
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detection kit according to the manufacturer’s instructions.  The membrane was
covered with plastic wrap on a glass plate and exposed to Fuji Medical X-ray film.
X-ray film was developed by soaking the film in Kodak GBX developer for 1-5
minutes, rinsing in H2O, soaking in fixer and replenisher for 1-5 minutes, followed
with a final rinsing in H2O.
Analysis of Total RNA Via Aligent Bioanalyzer
E. coli cells were grown as described previously with various
concentrations of hygromycin B and without hygromycin B. Total RNA was
extracted as described above.  Total RNA was examined using an Aligent
Bioanalyzer 2100 and the RNA 6000 lab on a chip.  Five microliters (200 ng/µl) of
sample from total RNA was loaded onto each well of the RNA 6000 chip.
Sample prep, loading procedure, and run were carried out according to
manufacturer’s recommendations for total RNA analysis.
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CHAPTER 3
RESULTS
Effects of Hygromycin B on Growth Rate, Protein Synthesis, Cell Viability, and
Ribosomal Subunit Formation in Escherichia coli
MIC Determination of Hygromycin B in E. coli
Minimal inhibitory concentration (MIC) represents the minimal
concentration of antibiotic that will halt visible cell growth.  An MIC value was
determined prior to other experiments in order to find a suitable concentration
range of antibiotic.  The MIC value for hygromycin B in E. coli D10-1 growing in
TSB at 37°C was 150 µg/ml (Table 2).  Sub-inhibitory concentrations of drug
were chosen based on the results of the MIC.  Sub-inhibitory amounts of drug
suppress cell growth without halting growth completely.  The sub-inhibitory
concentrations chosen based on the MIC value spanned a range from 0-100
µg/ml.
Effects of Hygromycin B on Protein Synthesis
Aminoglycoside antibiotics are well-known inhibitors of translation in
bacteria cells.  The rate of protein synthesis in growing E. coli cells was
examined by measuring the incorporation of 35S-methionine into cellular proteins.
Figure 9A shows the rate of incorporation of 35S-methionine with increasing
concentrations of hygromycin B.  The inhibitory effect on protein synthesis is
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represented in Figure 9B as a percent of control [35S-methionine incorporation at
15 minutes graphed as a percent of control protein synthesis].  The IC50 is given
in Table 2.
 
Figure 9  Inhibition of protein synthesis by hygromycin B.  (A) Inhibition of 35S-
methionine incorporation in E. coli D10-1 cells treated with hygromycin B at (<)
0 µg/ml, (‡) 15 µg/ml, (o) 30 µg/ml, (s) 45 µg/ml, (c) 60 µg/ml, (=) 75 µg/ml.
(B) Concentration dependent inhibition of 35S-methionine incorporation in E. coli
D10-1 cells at 37 °C treated with hygromycin B graphed as a percent of control
protein synthesis.  Arrow indicates IC50 value.  Bars indicate standard error.
Results are the mean of two experiments.
B
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Table 2  MIC and IC50 values for hygromycin B in E. coli cells.
a Cell number was determined by colony counting after dilution of 10-5 and plating on
TSB agar plates.
b Growth rate was determined by cell density (measured in Klett units) over time.
cProtein synthesis rates was determined by 35S-methionine incorporation.
d Subunit formation was determined by 3H-uridine incorporation.
Effects of Hygromycin B on Growth Rate and Cell Viability.
The inhibition of cell viability and cellular growth rate is consistent with the
demonstrated inhibitory effects of hygromycin B on translation.  As shown in
Figures 10A and 10B, hygromycin B diminished the number of viable cells and
increased the doubling time in a concentration dependent fashion.  Hygromycin B
inhibited viable cell numbers by 50% at a concentration of 20 µg/ml.  Growth rate
was reduced by half at a concentration of 25 µg/ml.
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Figure 10  Inhibition of growth rate and cell viability in E. coli cells with increasing
concentrations of hygromycin B.  (A) Percent decrease in growth rate with
increasing concentrations of hygromycin B ( n ).  (B) Percent decrease in viable
cell numbers with increasing concentrations of hygromycin B ( g ).  Arrows
indicate IC50 values. Bars indicate standard error.  Results are the mean of two
determinations.
Inhibition of Ribosomal Subunit Formation by Hygromycin B
The effect of hygromycin B on ribosomal subunit formation was examined
in growing E. coli cells.  The concentration dependence of ribosomal subunit
assembly was measured by examining sucrose gradient profiles of ribosomal
subunits labeled with 3H-uridine during growth in the presence and absence of
hygromycin B.  Figures 11A-F show sucrose gradient profiles of lysates from
cells grown without antibiotic or in the presence of the drug.  The 30S ribosomal
subunit amount was reduced more so than the 50S amount initially.  There was
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also an increased amount of fragmented RNA that accumulated in the top
fractions of the gradients from cells treated with hygromycin B.  Figure 12 shows
the concentration dependent inhibitory action on assembly of the 30S ribosomal
subunit by hygromycin B.  Increasing concentrations of the antibiotic lowered 30S
particle amounts in growing E. coli cells.  The amounts of 50S ribosomal subunits
were also reduced.  The decline in 50S ribosomal subunit amounts was most
apparent at higher concentrations of hygromycin B.  IC50 values for inhibition of
ribosomal subunit formation are given in Table 2.
Pulse-chase kinetic analysis of ribosomal subunit assembly
Pulse-chase kinetic analysis was also used to measure the rates of
ribosomal subunit synthesis in growing cells.  Figures 13A and 13B show the
pulse chase kinetic analysis of ribosomal subunit formation in control and
hygromycin B treated cells.  In the absence of the antibiotic 30S ribosomal
subunit formation was complete in 15 minutes and 50S subunit formation
reached a plateau in 30 minutes.  When cells were treated with hygromycin B,
30S subunit formation did not reach control levels until 60 minutes and 50S
ribosomal subunit amounts were estimated to reach control levels in
approximately 120 minutes.   30S and 50S ribosomal subunit formation rates
were inhibited equally relative to control rates.
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Figure 11  Effect of hygromycin B on ribosomal subunit amounts.  (A) Sucrose
gradient profiles of E. coli grown in the absence of antibiotic and in the presence
of (B) 15 µg/ml hygromycin B (C) 30 µg/ml hygromycin B.  (D) 45 µg/ml
hygromycin B (E) 60 µg/ml hygromycin B  (F) 75 µg/ml hygromycin B.
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Figure 12  Concentration dependent inhibition of ribosomal subunit assembly in
E. coli cells at 37°C treated with hygromycin B.  Inhibition of 30S assembly (®),
and inhibition of 50S assembly ( n ).  Arrows indicate IC50 values for 30S (red
arrow) and 50S (green arrow) ribosomal subunit formation.  Results are the
mean of two determinations.  Bars indicate standard error.
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Figure 13 3H-uridine pulse and chase labeling kinetic analysis of ribosomal
subunit formation.  Ribosomal subunit assembly kinetics in E. coli at 27 °C.  (A)
Assembly of 30S subunits ( n )  and 50S subunits (s) without hygromycin B.
(B) Assembly of 30S subunits ( n ) and 50S subunits (s) with hygromycin B (50
µg/ml). Results are the mean of two determinations.  Bars indicate standard
error.
Northern Hybridization Analysis of 16S rRNA Fragmentation
Previous work with 50S ribosomal subunit inhibitors has shown that 23S
rRNA fragments accumulate upon drug treatment.  These are in greater amounts
in E. coli strains containing one or more mutations in specific RNase genes that
may be involved in the turnover of antibiotic-stalled rRNA (Silvers and Champney
2005).  RNase II, RNase III, and PNPase were shown to be involved in the
turnover of stalled 23S rRNA.  Studies examining paromomycin and neomycin
have revealed an accumulation of fragmented RNA in the top portion of gradients
from cells treated with these aminoglycoside antibiotics (Mehta and Champney
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2002; Mehta and Champney 2003).  Broken down rRNA as well as smaller tRNA
and mRNA sediment in the top fractions of sucrose gradients.  It is apparent from
Figure 11(A-F) that in cells treated with hygromycin B there are substantially
higher amounts of RNA oligonucleotides in the top fractions compared to 30S
and 50S subunit amounts.  My goal was to determine if the 30S ribosomal
subunit inhibitor hygromycin B had any effect on accumulation of 16S rRNA
fragments and to determine the enzymes involved in turnover of 16S rRNA.
 Analysis by Northern hybridization with 16S and 23S rRNA-specific
probes was performed on RNA isolated from the top fractions of sucrose
gradients of lysates from E. coli strains grown with hygromycin B.  The
ribonuclease mutant strains examined in this study included D10-1 (RNase I-),
SK4803 (RNase II-), CA244 (PNPase-), and SK7622 (RNase III-) deficient strains.
Table 1 lists the strains of E. coli used in this experiment along with their
respective phenotype and genotypes.  Figure 14 shows the autoradiograph of the
Northern blots hybridized with the 16S and 23S rRNA specific probes.
Hybridization of 16S rRNA specific probe with rRNA isolated from the top fraction
occurred in each strain that had been treated with hygromycin B.  SK7622 and
SK4803 strains contained larger amounts of 16S fragments in comparison to
D10-1.  D10-1 exhibited very little accumulation of 16S oligonucleotides with or
without the presence of hygromycin B.  RNase III deficient SK7622 had
particularly high amounts of 16S fragmentation.  The size of RNA fragments
hybridized to 16S rRNA specific probes were estimated to be 900-200
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nucleotides.  Size was calculated using a low range RNA ladder (Fermentas) that
was biotin labeled using the Mirus Label-It kit.  No accumulation of 23S RNA was
visualized in the top fractions (Figure 14B).
Figure 14  Northern hybridization analysis of rRNA.  RNA was isolated from the
top regions of sucrose gradients from cells grown without and with hygromycin B
(50 µg/ml).  The RNA was separated on a 1.5% agarose gel and a blot of the gel
was hybridized with a biotin labeled 16S specific DNA probe (A) or a 23S specific
DNA probe (B). 16S rRNA was used as a standard along with a biotin labeled
low-range ladder.
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Analysis of Total RNA Via Agilent Bioanalyzer
Total RNA was examined in E. coli cells treated with hygromycin B at
various concentrations of antibiotic and in control cells using the RNA 6000 lab
chip kit and Bioanalyzer 2100 (Agilent).  With increasing concentrations of
hygromycin B there was an increase in the amount of RNA accumulation
corresponding to a 16S rRNA precursor.  There also was a concentration
dependent decrease in the amount of 16S ribosomal RNA present in the
antibiotic treated cells along with an increase in the amount of small fragments of
RNA.  Table 3 lists the percentage of total area for each peak corresponding to
small RNA, 16S rRNA, precursor to the 16S rRNA, and 23S rRNA.  Figure 15(A-
B) shows the fluorescent chromatograph and virtual gel from the Agilent
Bioanalyzer analysis.
Table 3  Percent of total area for fluorescent chromatograph peaks representing
small RNA, 16S rRNA, precursor for the 16S rRNA, and 23S rRNA from E. coli
D10-1 with increasing concentrations of hygromycin B.  Results are the mean of
two determinations.  Standard error of the mean is represented.
 Percent Total Area 
Concentration 
of hygromycin 
B (µg/ml) 
Small 
RNA 
16S Precursor 
to the 16S 
23S  
0 
25 
60.9±0.1 
59±1.0 
9.6±0.1 
10.4±0.1 
0.3±0.1 
0.5±0.04 
13±1.2 
13.5±0.2 
50 62.8±0.8 10.4±0.5 0.75±0.2 12.5±0.6 
75 64.5±1.5 7.3±0.05 1.1±0.2 12.7±0.3 
100 68.8±0.8 4.8±0.05 1.2±0.1 10±0.15 
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Figure 15  Agilent bioanalyzer analysis of total RNA from E. coli cells treated with
hygromycin B.  (A) Fluorescent chromatograph showing the intensity of labeled
RNA peaks in samples of total RNA extracted from control E. coli cells (red line)
and cells treated 100 µg/ml of hygromycin B (blue line).  (B) Virtual gel produced
by the Agilent software based on the results from the fluorescent chromatograph.
B
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The Effect of Quinupristin-Dalfopristin and XRP 2868 on Cellular Growth Rates,
Cell Viability, Protein Synthesis, and Ribosomal Subunit Formation in H.
influenzae, S. aureus and S. pneumoniae.
  
MIC Determination of Quinupristin-Dalfopristin and XRP 2868.
Minimal inhibitory concentrations (MIC) for both antibiotics were
determined for each organism and are listed in Table 4.  The values were in good
agreement with those found by Pankuch and others (2003).
  
Effects of Quinupristin-Dalfopristin and XRP2868 on Protein Synthesis
Streptogramin antibiotics are well-known inhibitors of translation in bacteria
cells.  Quinupristin-dalfopristin kills cells by inhibiting protein synthesis and 50S
subunit formation ( Lamb and others 1999; Champney and Tober 2000).  Protein
synthesis rates in growing cells were measured by the incorporation of 35S-
methionine into cellular proteins.  Figure 16 A-C illustrates the effect of increasing
concentrations of each drug on the rate of translation.  Both drugs inhibited
translation at a lower concentration in S. aureus and S. pneumoniae compared
with H. influenzae.  XRP 2868 was the more effective inhibitor of protein
synthesis in all three organisms examined. IC50 values for translational inhibition
are presented in Table 4.  Inhibition of protein synthesis by each drug is
represented as a percent of control 35S-methionine incorporation.
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Figure 16  Inhibition of protein synthesis by quinupristin-dalfopristin and XRP
2868.  Streptogramin concentration dependent inhibition of protein synthesis
rates.  Protein synthesis rates were measured by 35S-methionine incorporation in
(A) H. influenzae, (B) S. aureus and (C) S. pneumoniae in the presence of
increasing concentrations of XRP 2868 ( ®, dashed line ) and quinupristin-
dalfopristin ( O, solid line ).  Power best fit lines are shown for S. aureus and S.
pneumoniae.  Linear best fit lines are shown for H. influenzae.  Bars indicate
standard error.  Arrows indicate IC50 values for quinupristin-dalfopristin (open
arrows) and XRP 2868 (filled arrows).  Results are the mean of three
determinations.
ragments
16S rRNA Fragments
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Table 4  MIC and IC50 values for streptogramin antibiotic inhibition of cell viability,
protein synthesis and 50S ribosomal subunit formation In three microorganisms.
a Cell number was determined by colony counting after dilution of 10-5 and plating
on appropriate nutrient agar plates.
b Growth rate was determined by cell density (measured in Klett units) over time.
c Protein synthesis rates was determined by 35S-methionine incorporation.
d Subunit formation was determined by 3H-uridine incorporation.
Effects of quinupristin-dalfopristin and XRP 2868 on cell viability
The inhibition of cell viability is consistent with the demonstrated inhibitory
effects of each antibiotic on translation.  Quinupristin-dalfopristin and XRP 2868
Organism Antibiotic aCell
Number
bProtein
Synthesis
c50S
subunit
amount
MIC
(µg/ml)
H. influenzae Quinupristin-
dalfopristin 2.2 3 3.6 4
XRP2868 0.3 0.6 0.9 1
S. pneumoniae Quinupristin-
dalfopristin 0.07 0.12 0.24 1
XRP2868 0.07 0.07 0.11 0.5
S. aureus Quinupristin-
dalfopristin 0.13 0.11 0.2 2
XRP2868 0.05 0.07 0.4 1
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both reduced the viable cell count in each organism tested in a concentration
dependent manner, consistent with the inhibitory effects seen on protein
biosynthesis.  XRP 2868 exhibited the greatest effect on each organism
examined.  The results are shown in Figure 17 A-C and IC50 values for the
antibiotics are shown in Table 4.  The growth rate of each organism also declined
in proportion to the drug concentration (data not shown).
Figure 17  Streptogramin concentration dependent inhibition of cell viability.
Inhibition of cell viability by colony counting in (A) H. influenzae, (B) S. aureus
and (C) S. pneumoniae in the presence of XRP 2868 (®, dashed line) and
quinupristin-dalfopristin (O, solid line).  Linear best fit lines are shown for H.
influenzae and power best fit lines are shown for S. aureus and S. pneumoniae.
Bars indicate standard error.  Arrows mark IC50 values for XRP 2868 (filled
arrows) and quinupristin-dalfopristin (hollow arrows). Results are the mean of
three determinations.
56
Inhibition of ribosomal subunit formation by quinupristin-dalfopristin and XRP
2868
Each antibiotic was also examined for its effects upon ribosomal subunit
formation. The concentration dependence of ribosomal subunit assembly was
measured by examining sucrose gradient profiles of ribosomal subunits labeled
with 3H-uridine during growth in the presence and absence of each drug in each
organism.  Both drugs showed a concentration dependent inhibition of 50S
ribosomal subunit formation.   XRP 2868 was more effective than quinupristin-
dalfopristin at inhibiting 50S ribosomal subunit formation, inhibiting assembly by
half at 2-4 fold lower concentrations than quinupristin-dalfopristin, with the
exception of S. aureus that was nearly equivalent. The results for inhibition of
50S particle synthesis are illustrated in Figure 18A-C. IC50 values for each
antibiotic are shown in Table 4.
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Figure 18  Streptogramin concentration dependent inhibition of 50S ribosomal
subunit assembly.  Inhibition of 50S subunit amounts from 3H-uridine labeled
ribosomal subunits separated by sucrose gradient centrifugation in (A) H.
influenzae, (B) S. aureus and (C) S. pneumoniae in the presence of XRP 2868
(©, dashed line ) and quinupristin-dalfopristin (O, solid line ).  Linear best fit lines
are shown for H. influenzae and power best fit lines are shown for S. aureus and
S. pneumoniae. Arrows mark IC50 values for  XRP 2868 (filled arrows) and
quinupristin-dalfopristin (hollow arrows). Results are the mean of three
determinations.  Bars indicate standard error.
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CHAPTER 4
DISCUSSION
The aminoglycoside hygromycin B and the streptogramin compounds
quinupristin-dalfopristin and XRP 2868 are all well known translational inhibitors.
Hygromycin B acts specifically on the 30S subunit and the streptogramin
compounds quinupristin-dalfopristin and XRP 2868 specifically inhibit 50S
ribosomal subunit function.  The mechanism for their inhibition of translation has
been well studied; however, these antibiotics have not been examined prior to
this study for their ability to inhibit ribosomal subunit formation (Brodersen and
others 2000; Harms and others 2004).  Ribosomal subunit formation is a critical
life process that would make an ideal target for antimicrobial agents (Champney
2003).  This work has shown that hygromycin B inhibits 30S ribosomal subunit
assembly specifically and that quinupristin-dalfopristin and XRP 2868 act to
inhibit 50S ribosomal subunit synthesis.  Studies of this nature provide a better
understanding of the classes of antibiotics that specifically target ribosomal
subunit formation and the discrepancies within each class will aid future drug
development in this novel target area.
It is known that aminoglycoside antibiotics inhibit translation by binding to
the 30S ribosomal subunit.  Recent studies have shown that the aminoglycoside
antibiotics neomycin and paromomycin posses a secondary inhibitory target,
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preventing the formation of functional 30S ribosomal subunits (Mehta and
Champney 2002; Mehta and Champney 2003).
Previous studies have shown that these antibiotics prevent translation and
ribosomal subunit formation with near equal action in growing E. coli cells (Mehta
and Champney 2002).  An interesting difference was seen in the effect of
hygromycin B on protein synthesis and ribosomal subunit assembly with this
antibiotic.  Hygromycin B was a stronger inhibitor of translation than 30S
ribosomal subunit formation with IC50 values of 16 µg/ml and 65 µg/ml
respectively.  Inhibition of growth rate and total viable cell numbers were in
accordance with the reduction of protein synthesis rates (Table 2).
Hygromycin B has recently been shown to affect a ribosomal ATPase
RbbA that is required for protein synthesis (Ganoza and Kiel 2001).  RbbA is an
ATPase that binds to the 30S subunit near the E-site and functions to aid ejection
of tRNA from the E-site (Xu and others 2006).  Hygromycin B binds near the
binding site for RbbA disrupting the binding of the ATPase.  Hygromycin B has
been shown to inhibit 70-80% of the ATPase activity of 70S ribosomes whereas
similar aminoglycoside antibiotics did not have the same effect; neomycin and
streptomycin inhibited only 10-25% of ribosomal ATPase activity (Ganoza and
Kiel 2001). The effects of hygromycin B on this enzyme may contribute to the
marked difference seen in its inhibitory effect on translation compared to other
aminoglycosides.
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Inhibition of 30S and 50S ribosomal subunit assembly by hygromycin B
was also examined.  Inhibition of 50S ribosomal subunit assembly by most 50S
protein biosynthesis inhibitors does not affect 30S subunit synthesis (Champney
2001).  However, 50S ribosomal subunit formation may be affected by inhibitors
of 30S ribosomal subunit assembly.  Both neomycin and paromomycin have
been shown to cause a reduction in 50S ribosomal subunit formation in E. coli
and S. aureus at higher concentrations of drug (Mehta and Champney 2002;
Mehta and Champney 2003).  Hygromycin B demonstrated a similar reduction
pattern in the amounts of 50S ribosomal subunit.  The indirect action of these
antibiotics on the 50S subunit has been attributed to a downstream effect (Mehta
and Champney 2002; Mehta and Champney 2003).  Small subunit (30S) particle
biosynthesis precedes 50S ribosomal subunit synthesis; therefore, any effect on
30S formation could have a nonspecific downstream action of slowing or halting
50S biosynthesis.  The effects are similar to that found with polar effect on genes
transcribed from a multi-gene transcript.  When transcription of a gene upstream
is affected, all of the genes downstream are also affected while any genes farther
upstream remain unaffected.  Figure 19A-B illustrates the tandem synthesis of
the 30S and 50S particles.
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Figure 19  Tandem synthesis of the 30S and 50S ribosomal subunits in E. coli
cells.  (A) Transcripts for 16S and 23S rRNA genes are linked.  (B) Formation of
30S and 50S ribosomal subunits in E. coli cells.
Pulse-chase kinetic analysis of ribosomal subunit formation in cells treated
with hygromycin B supports a nonspecific effect on 50S particle synthesis.  In
control cells there was approximately twice the amount of 50S ribosomal
subunits compared to 30S subunits and the amount of time required to
ragments
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synthesize a 50S particle was about twice as long as a 30S subunit.  This ratio in
quantity and synthesis rate for the ribosomal subunits was consistently seen.  In
drug-treated cells the rate for synthesis of the 30S and 50S increased to 60
minutes and ~120 minutes before reaching control amounts, respectively.  The
results for the pulse-chase kinetic analysis indicated an equal inhibition of the
rate of 30S and 50S ribosomal subunits (Figure 13A and 13B).  An equivalent
effect on 30S and 50S subunit assembly rates is expected if only the 30S particle
formation is being affected by an antibiotic.  An equal decline in 50S subunit
formation has been observed in previous studies with neomycin and
paromomycin (Champney and Mehta 2002; Champney and Mehta 2003).  The
theory for this indirect effect on the 50S has been explained above.
Northern blot analysis with 16S rRNA specific probe on small RNA
fragments isolated from hygromycin B treated cells showed increased
accumulation of fragmented 16S rRNA (Figure 14A-B).   Samples from SK7622
(RNase II-) and SK4803 (RNase III-) strains treated with drug contained larger
amounts of 16S fragments in comparison to D10-1 (RNase I-).  Previous work
with 23S assembly inhibitors has also shown these enzymes to also be important
in the turnover of stalled 50S intermediate (Silvers and Champney 2005).  There
were only trace amounts of 16S fragments in D10-1 treated with hygromycin B.
The small amount of fragment build up in these cells indicates that RNase I is not
an important enzyme for the turnover of stalled 16S particle.  Silvers and
Champney (2005) also found this to be the case with 50S intermediate turnover;
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D10-1 behaved similarly to wild type cells.  One interesting difference between
23S and 16S turnover was the size of rRNA fragments produced.  Turnover of
azithromycin stalled 50S subunit intermediates gave 23S rRNA in the sizes of
500 and 1000 base pairs were observed (Silvers and Champney 2005).  The 16S
fragments that were produced during hygromycin B treatment were in the size of
200-900 base pairs.   The difference in size is likely because of differences in the
16S and 23S rRNA, the differences in the proteins interacting with the rRNA in
the precursor forms of the 30S and 50S subunits and how these are recognized
by RNases involved in turnover.
The large amounts of 16S fragmentation in E. coli strains SK7622 and
SK4803 could be an indication of the importance of RNase II and III in the break
down of ribosomal subunit precursor that forms during treatment with antibiotics
which inhibit assembly. The model in Figure 2 predicts that RNase enzymes are
necessary for the removal/recycling of stalled precursor from cells treated with
assembly inhibiting antibiotics.  RNase III deficient SK7622 had particularly high
amounts of 16S particle accumulation implicating this RNase as an especially
important factor in the turnover of 30S ribosomal subunit precursor that is formed
during treatment with hygromycin B.  RNase III is an important endoribonuclease
that plays a role in the processing of both 16S and 23S rRNA (Srivastava and
Schlessinger 1990).  Hybridization with a 23S specific probe showed no
accumulation of 23S fragments in any of the drug treated samples indicating that
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hygromycin B is specifically targeting only the 30S ribosome in assembly and
translation (Figure 14B).
Examination of total RNA from hygromycin B treated E. coli cells using the
Agilent bioanalyzer also supported specific inhibition of 16S rRNA.  Total RNA
analysis showed an increase in small fragments of RNA and a decrease in the
amount of RNA corresponding to 16S rRNA.  Meanwhile the amount of
fragments of RNA corresponding to the 16S rRNA precursor increased (Table 3,
Figure (15A-B).  A decrease in the amount of RNA corresponding to the 23S was
also seen.
Hygromycin B binds with specificity only to the 30S ribosomal subunit and
inhibits translation by interfering with the A, P, and E sites only on this subunit
(Brodersen and others 2000).  Hygromycin B has been shown to bind to a part of
helix 44 (H44) that changes position during translocation and it is believed that
hygromycin B binding to H44 restricts the movement of this helix during protein
synthesis (Frank and Agrawal 2000).  It is possible that hygromycin B binding to
this helix could also restrict movement necessary to form functional 30S subunits
and in so doing prevent conformational rearrangement required for processing of
the 16S rRNA transcript and subsequent 30S ribosomal subunit maturation.
The binding of hygromycin B can be interrupted by modification of the
antibiotic by phosphotransferases or mutation of target rRNA bases.  The
hygromycin phosphotransferase enzyme is found in the hygromycin B producing
organism Streptomyces hygroscopicus (Malpartida and others 1983; Bilang and
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others 1991).  The gene for hygromycin phosphotransferase has also been
located on plasmids in bacteria found in animals treated with the antibiotic.  The
resistance gene has also been discovered on R plasmids in 2 clinical strains of
bacteria, Escherichia coli and Klebsiella pneumoniae (Gomez-Lus R 1998). 
Mutation of rRNA is another mechanism of resistance to hygromycin B.  It
has been shown in single rRNA allelic derivatives of Mycobacterium smegmatis
that point mutations at or near the hygromycin B binding site in helix 44 of 16S
rRNA confer resistance to the antibiotic (Pfister and others 2003).  Studies with
E. coli and Tetrahymena thermophila mutants concur (Spangler and Blackburn
1985; De Stasio and Dahlberg 1990).
Several crystal structures of aminoglycosides complexed with 30S
subunits or 16S fragments have been resolved and are the basis for new
avenues of structure based drug design (Brodersen and others 2000; Vicens and
Westhof 2003).  A group at Anadys Pharmaceuticals, Inc. has designed hybrid
aminoglycoside ligands.  These ligands combine components of hygromycin B
and paromomycin or neomycin B and are designed to make the most of subtle
differences in binding of these antibiotics onto the 30S ribosomal subunit near
helix 44 and the decoding site (Zhou and others 2005; Murray and others 2006).
 Crystal structures of antibiotic bound to intermediate particles in ribosomal
subunit assembly have not yet been resolved.  Antibiotic hybrids designed based
on their ability to bind these intermediate structures could be more effective
antibiotics than their parent drugs.  Inhibition of subunit assembly would halt
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protein synthesis before it began by preventing the formation of functional
ribosomes.  Targeting of ribosomal subunit formation should create an even
greater bactericidal effect in comparison to inhibition of translation.  It is important
to examine other antibiotics for their inhibitory effects on this possible target.
 This study also examined the effects of several new streptogramin
compounds for their effects on ribosomal subunit formation.  The development of
new antimicrobial agents is critical for overcoming the problem of microbial drug
resistance.  Both the development of new antibiotics like linezolid (Livermore
2003) and the modification of existing compounds such as the aminoglycoside
hybrid ligands are required.  Quinupristin-dalfopristin is a streptogramin antibiotic
that has been in clinical use since 1999 for the treatment of multi-resistant
infections of Gram-positive bacteria.  XRP 2868 (also known as NXL 103) is a
new oral streptogramin derived from quinupristin-dalfopristin that is showing
great promise as a treatment option in multi-resistant Gram-positive infections.
XRP2868 has been shown to be more inhibitory than nine other antibiotics tested
against a variety of Gram-positive clinical isolates (Goldstein and others 2005).
The new antibiotic has also shown better activity against H. influenzae and S.
pneumoniae than its parent drug combination of quinupristin-dalfopristin in MIC
assays (Pankuch and others 2003).
Antibiotics that bind to the large 50S ribosomal subunit of bacterial
ribosomes inhibit both the translational activity of the subunit and specifically
prevent its formation in cells (Champney 2003).  Both A and B-type
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streptogramins have this dual activity (Champney and Tober 2000).  The goal of
this study was to compare the inhibitory effects of XRP 2868 with quinupristin-
dalfopristin on cellular functions including ribosome function and assembly in b-
lactamase-positive Haemophilus influenzae, methicillin-resistant Staphylococcus
aureus, and erythromycin-resistant S. pneumoniae strains.  These resistant
strains were chosen because they are commonly found in human infections and
they often respond to streptogramin antibiotics (Lamb and others 1999).  Minimal
inhibitory concentrations (MIC) for both antibiotics were determined for each
organism and are listed in Table 4.  The values for S. pneumoniae and H.
influenzae are in good agreement with those found by Pankuch and others
(2003).
Quinupristin-dalfopristin kills cells by inhibiting protein synthesis and 50S
subunit formation (Lamb and others 1999; Champney and Tober 2000).  Both
drugs inhibited translation at a lower concentration in S. aureus and S.
pneumoniae compared with H. influenzae.  XRP 2868 was the more effective
inhibitor of protein synthesis in all three organisms examined (Figure 16).  IC50
values for translational inhibition are summarized in Table 4.
Each antibiotic was also examined for its effects upon ribosomal subunit
formation.  Previous work has shown that the streptomycin compound
virginiamycin caused a specific decrease in the amount of 23S rRNA in Bacillus
subtilis cells treated with the antibiotic (Cocito 1969; Cocito 1971; Cocito 1973).
It has been demonstrated that the streptogramin B component is responsible for
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the reduction in 50S ribosomal subunit formation by several streptogramin
compounds in B. subtilis and S. aureus while the A component functions to inhibit
protein synthesis (Cocito 1969; Cocito 1971; Cocito 1973; Champney and Tober
2000).  Quinupristin-dalfopristin and XRP 2868 showed a concentration
dependent inhibition of 50S ribosomal subunit formation with XRP 2868 being as
effective as quinupristin-dalfopristin at a 2-4 fold lower concentration of drug with
the exception of S. aureus (Figure 18A-C). The major effect of both drugs in S.
aureus was inhibition of translation and XRP 2868 reduced protein biosynthesis
by half at a concentration of drug two fold lower than quinupristin-dalfopristin.
There was not a specific decline in 30S subunit amounts in cells treated with
each antibiotic (data not shown).
Resistance to quinupristin-dalfopristin, XRP 2868 and other streptogramins
is incurred by enzymatic modification of the compound, active transport or efflux
by an ATP powered pump, and alteration of the target site.  Because there are
different binding sites for each of the components, the mechanisms of resistance
are also different.  Resistance to group B components most often occurs though
cross resistance provided by erm genes encoding erythromycin methyl
transferases.  These enzymes transfer methyl groups onto an adenine residue in
the 23S rRNA that results in decreased binding of macrolide, lincosamide, and
streptogramin B antibiotics.  Other mechanisms of resistance to group B
streptogramins are rare and specific for certain strains of Gram-positive bacteria.
Group A resistance is most often mediated by genes that encode
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acetyltransferases that inactivate the antibiotic or by genes which encode efflux
pumps that actively transport the antibiotic out of the cells (Thal and Zervos
1999).  Quinupristin-dalfopristin has been available clinically only since 1999.
Resistant isolates containing one or more of the above mentioned resistance
factors have already begun to appear in the clinical setting (Bozdogan and
Leclercq 1999; Lina and others 1999; Malbruny and others 2002).  The need to
expand the antibiotic arsenal is ever present.  Improving existing antibiotics and
seeking out new targets for existing antimicrobial agents are ways to strengthen
our stand in the war against antibiotic resistant pathogens.
The results show that XRP 2868 is a more effective inhibitory agent
against methicillin-resistant S. aureus, erythromycin-resistant S. pneumoniae,
and b-lactamase-positive H. influenzae than quinupristin-dalfopristin.  This study
is the first to test the inhibitory effects of this new compound on cellular functions
in a MRSA strain and demonstrates that this drug is effective against this
resistant organism.  The IC50 values for inhibition of protein synthesis by XRP
2868 in all bacteria examined were 2-5 fold lower than that of quinupristin-
dalfopristin.  50S subunit amounts were reduced in proportion to the decline in
protein synthesis in all organisms.  The inhibition of 50S subunit amounts
indicates that cell killing was a result of the antibiotics’ effect on translation and
the assembly of 50S subunits.  Understanding the relationship between structural
variance and differential inhibition of cellular function in target organisms is
important for the development of effective antibiotics (Chu and others 1996).
70
More studies of this nature with other modified streptogramin compounds would
be helpful in this regard.
This work is a continuation of studies examining possible ribosomal
subunit assembly inhibitors.  More studies such as this one are needed to
elucidate the potential of ribosomal subunit assembly as an antibiotic target and
increase our understanding of the mechanism behind specific inhibition of this
vital cellular function.
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ABBREVIATIONS
30S ……………………  Small subunit of ribosome
50S …………………….  Large subunit of ribosome
DNA …………………….  Deoxyribonucleic acid
MIC …………………….. Minimal inhibitory concentration
RNA …………………….. Ribonucleic acid
rRNA ……………………... Ribosomal RNA
S-buffer, R-buffer ………………. Subunit buffer, Ribosome buffer
IC50 ……………………… 50% inhibitory concentration
TSB ……………………… Tryptic soy broth
MRSA ...…………………… Methicillin resistant Staphylococcus aureus
RNase, PNPase  ……………….  Ribonuclease, Polynucleotide Phosphorylase
TCA    ……………………… Trichloro-acetic acid
SDS   ………………………. Sodium lauryl sulfate
DOC ………………………. Deoxycholic acid sodium salt
EDTA ………………………. Disodium ethylenediamine-tetraacetate
PMSF ………………………. Phenylmethanesulfonyl fluoride
MOPS ………………………. 3-(N-Morpholino)-propanesulfonic acid
SAS-buffer  ……………………….. S. aureus subunit buffer
PCR  ……………………….. Polymerase chain reaction
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